Only very recently studies were conducted in order to evaluate the impact of regulatory T (Treg) cells in the pathophysiology of atopic dermatitis (AD). Nine adult patients with moderate-to-severe AD in riacutization period of a chronic disease were given tacrolimus ointment, while seven hydrocortisone butyrate ointment, that served as controls. We performed lesional-skin biopsies before and after treatment, that were stained immunohistochemically with monoclonal antibodies to CD4, CD25, forkhead/winged helix transcription factor (FoxP3), interleukin (IL)-10 and transforming growth factor (TGF)-beta. CD4+ cells were significantly reduced in post-treatment series. Tacrolimus treatment achieved a significant reduction of CD25+ cells. FoxP3+ cells were present in untreated AD lesions. Both treatments did not significantly modify the number of FoxP3+ cells. The number of IL-10+ cells increased in post-treatment series. Tacrolimus enhanced the production of TGF-beta, while hydrocortisone did not. Restoration of TGF-beta-producing Treg cells may represent another important pharmacodynamic effect of tacrolimus on AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10875-006-9034-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Topical Anti-Inflammatory Effects of Quercetin Glycosides on Atopic Dermatitis-Like Lesions: Influence of the Glycone Type on Efficacy and Skin Absorption.
Inflammation
January 2025
Research Center for Food and Cosmetic Safety and Center for Drug Research and Development, Chang Gung University of Science and Technology, Kweishan, Taoyuan, Taiwan.
Atopic dermatitis (AD) is a multifaceted inflammatory skin condition characterized by the involvement of various cell types, such as keratinocytes, macrophages, neutrophils, and mast cells. Research indicates that flavonoids possess anti-inflammatory properties that may be beneficial in the management of AD. However, the investigation of the glycoside forms for anti-AD therapy is limited.
View Article and Find Full Text PDFSymmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a rare, symmetrical skin eruption triggered by various medications, predominantly beta-lactam antibiotics. We report the case of a 69-year-old male with moderate-to-severe ulcerative colitis who developed SDRIFE following the seventh intravenous administration of infliximab. The patient presented with symmetrical, pruritic erythema in the cubital and popliteal fossae, groins, gluteal and retroauricular regions without systemic involvement.
View Article and Find Full Text PDFLabial Adhesion Surgery Prior to Vaginal Delivery in a Patient With Vulvar Lichen Planus Causing Labial Adhesion: A Case Report.
Cureus
December 2024
Department of Obstetrics and Gynecology, Sendai City Hospital, Sendai, JPN.
Lichen planus is an inflammatory disease that affects the skin and mucous membranes, and although rare, it can manifest in the vulvar region. Vulvar lichen planus can occur in women of reproductive age and may cause vulvar adhesion, potentially complicating examinations and delivery during pregnancy. We report a case in which a pregnant woman with vulvar adhesion due to vulvar lichen planus successfully delivered vaginally following labiaplasty.
View Article and Find Full Text PDFTopical Tacrolimus in Vitiligo: Consensus Paper from the Pigmentary Disorders Society.
Clin Cosmet Investig Dermatol
December 2024
Consultant Dermatologist, Indore, Madhya Pradesh, India.
Background: Tacrolimus, a topical calcineurin inhibitor (TCI) with immunomodulatory effects, is considered a viable treatment option for vitiligo. A consensus building exercise was undertaken to determine the role and clinical utility of topical tacrolimus in the management of vitiligo using input from experts in the field of dermatology.
Methods: Seventeen experts collaborated to create consensus statements using a modified Delphi methodology.
English version of clinical practice guidelines for the management of atopic dermatitis 2024.
J Dermatol
December 2024
Medical Informatics and Management, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Article Synopsis
- The 2024 clinical practice guidelines for atopic dermatitis (AD) focus on effectively managing this condition characterized by itchy, relapsing eczema.
- The primary goal of treatment is to quickly induce remission by reducing skin inflammation and itching, primarily using topical anti-inflammatory medications.
- The updated guidelines introduce five new treatments and emphasize the importance of evaluating research and weighing the pros and cons of various medical options to enhance patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!